TEST CATALOG ORDERING & RESULTS SPECIMEN HANDLING CUSTOMER SERVICE EDUCATION & INSIGHTS
Test Catalog

Test ID: KI67    
Ki-67 (MIB-1) Immunostain, Technical Component Only

Useful For Suggests clinical disorders or settings where the test may be helpful

A marker of proliferation in neoplasms

Testing Algorithm Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

For the initial technical component only immunohistochemical (IHC) stain performed, the appropriate bill-only test ID will be reflexed and charged (IHTOI). For each additional technical component only IHC stain performed, an additional bill-only test ID will be reflexed and charged (IHTOA).

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Ki-67 (antibody clone MIB-1), is a nuclear protein playing a pivotal role in maintaining cell proliferation. Ki-67 is present in all non-G0 phases of the cell cycle. Beginning in the mid-G1, the level increases through S and G2 to reach a peak in M phase. In the end of M phase, it is rapidly catabolized. Ki-67 has been employed as a marker of proliferation and, hence, prognosis in neoplasms of many types, such as malignant lymphomas, prostatic and breast adenocarcinomas, astrocytic neoplasms, and soft tissue neoplasms.

Interpretation Provides information to assist in interpretation of the test results

This test includes only technical performance of the stain (no pathologist interpretation is performed). Mayo Clinic cannot provide an interpretation of tech only stains outside the context of a pathology consultation. If an interpretation is needed, refer to PATHC / Pathology Consultation for a full diagnostic evaluation or second opinion of the case. All material associated with the case is required. Additional specific stains may be requested as part of the pathology consultation, and will be performed as necessary at the discretion of the Mayo pathologist.

 

The positive and negative controls are verified as showing appropriate immunoreactivity and documentation is retained at Mayo Clinic Rochester. If a control tissue is not included on the slide, a scanned image of the relevant quality control tissue is available upon request. Contact 855-516-8404.

 

Interpretation of this test should be performed in the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Age of a cut paraffin section can affect immunoreactivity. Stability thresholds vary widely among published literature and are antigen-dependent. Best practice is for paraffin sections to be cut fresh.

Clinical Reference Recommendations for in-depth reading of a clinical nature

1. Yerushalmi R, Woods R, Ravdin PM et al: Ki67 in breast cancer: prognostic and predictive potential. Lancet 2010;11:174-183

2. Leonardo E, Volante M, Barbareschi M, et al: Cell membrane reactivity of MIB-1 antibody to Ki67 in human tumors: fact or artifact? Appl Immunohistochem Mol Morphol 2007;15(2):220-223

3. Potemski P, Pluciennik E, Bednarek AK, et al: Ki-67 expression in operable breast cancer: a comparative study of immunostaining and a real-time RT-PCR assay. Pathol Res Pract 2006;202:491-495

4. Li R, Heydon K, Hammond ME, et al: Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in Radiation Therapy Oncology Group Protocol 86-10. Clin Cancer Res 2004;10:4118-4124

5. Trihia H, Murray S, Price K, et al: Ki-67 expression in breast carcinoma-its association with grading systems, Clinical parameters, and other prognostic factors-a surrogate marker? Cancer 2003;97(5):1321-1331